WayPoint Biomedical, Inc. And Global Informatics Form New Joint Venture, World Wide Medical Systems, LLC
HUNTINGTON BEACH, Calif., (GVIPT), March 9 /PRNewswire-FirstCall/ -- WayPoint Biomedical Holdings, Inc. and Laguna Hills, CA based Global Informatics Technology, Inc. have completed and signed the definitive documents to form their new Joint Venture, World Wide Medical Systems, LLC (WWMS).
In addition to completing the JV agreement, $7.5 million in initial capital was secured to fund Global's manufacturing, and production capabilities, along with providing the working capital needed for WayPoint to begin forming the corporate operating structure of World Wide Medical Systems. The new JV will be responsible for the global commercialization of Global Informatics' patented, Smart Card based, Electronic Medical Records (EMR) System.
WayPoint CEO, Dennis Shepherd, states, "With the first round of financing secured and the initial traunce expected within the next two weeks, we are prepared to initiate the process of bringing this revolutionary healthcare technology to the world."
About WayPoint Biomedical
WayPoint Biomedical Holdings, Inc. , is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical, visit www.waypointbiomedical.com, www.drinkdetectiveusa.com.
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.
WayPoint Biomedical Holdings, Inc.CONTACT: Dennis Shepherd of WayPoint Biomedical Holdings, Inc.,+1-714-848-3200, dshepherd@waypointbiomedical.com; or Investor Relations,David Kugelman, +1-866-692-6847, for WayPoint Biomedical Holdings, Inc.